ImpaQ Ecosystem•Clarivate, Scopus & CORE Data
Clarivate WoS 2024 / 2025 Data
IMPAQ
WoS SCIE Q2Scopus Q1SCImago #3,914Hybrid

Psychopharmacology

Acronym:psph
•
Abbreviation (ISO):PSYCHOPHARMACOLOGY
•
Identifier (ISSN):0033-3158(Print)/1432-2072(Online)
•
Publisher:Springer Berlin Heidelberg
Clarivate IF (2026)
3.3– 0
Journal Impact Factor
IF Trend↓
WoS Quartile
Q2
WoS SCIEJCR Quartile
Clarivate WoS JCR
WoS Categories↓
JCR Release Date: 2026-06-17

Impact Factor Trend (2018–2026)

Clarivate IF trend for Psychopharmacology

WoS Q2
23563.2220183.4220193.1320204.5320214.4220223.420233.520243.320253.32026
Annual Impact Factor Metric
Current (2026):3.3
Scopus SJR & RankScopus Q1
1.147
#3,914

SCImago Journal Rank citation prestige weighting

Scopus Year: 2025
H-Index (2025)
224

224 papers with at least that number of citations each

WoS: SCIE / JCRQ2
Self-Citation Rate2.9%
Safe Level (< 15%)Warning Level (> 20%)
Self-citation below 15% indicates strong scholarly independence.
Volume & Open AccessHybrid
289articles/year
44.36% Gold OA•89.64% Original Research

Aims & Scope

Official Journal of the European Behavioural Pharmacology Society (EBPS) Psychopharmacology is an international journal that covers the broad topic of elucidating mechanisms by which drugs affect behavior. The scope of the journal encompasses the following fields: Human Psychopharmacology: Experimental This section includes manuscripts describing the effects of drugs on mood, behavior, cognition and physiology in humans. The journal encourages submissions that involve brain imaging, genetics, neuroendocrinology, and developmental topics. Usually manuscripts in this section describe studies conducted under controlled conditions, but occasionally descriptive or observational studies are also considered. Human Psychopharmacology: Clinical and Translational This section comprises studies addressing the broad intersection of drugs and psychiatric illness. This includes not only clinical trials and studies of drug usage and metabolism, drug surveillance, and pharmacoepidemiology, but also work utilizing the entire range of clinically relevant methodologies, including neuroimaging, pharmacogenetics, cognitive science, biomarkers, and others. Work directed toward the translation of preclinical to clinical knowledge is especially encouraged. The key feature of submissions to this section is that they involve a focus on clinical aspects. Preclinical psychopharmacology: Behavioral and Neural This section considers reports on the effects of compounds with defined chemical structures on any aspect of behavior, in particular when correlated with neurochemical effects, in species other than humans. Manuscripts containing neuroscientific techniques in combination with behavior are welcome. We encourage reports of studies that provide insight into the mechanisms of drug action, at the behavioral and molecular levels. Preclinical Psychopharmacology: Translational This section considers manuscripts that enhance the confidence in a central mechanism that could be of therapeutic value for psychiatric or neurological patients, using disease-relevant preclinical models and tests, or that report on preclinical manipulations and challenges that have the potential to be translated to the clinic. Studies aiming at the refinement of preclinical models based upon clinical findings (back-translation) will also be considered. The journal particularly encourages submissions that integrate measures of target tissue exposure, activity on the molecular target and/or modulation of the targeted biochemical pathways. Preclinical Psychopharmacology: Molecular, Genetic and Epigenetic This section focuses on the molecular and cellular actions of neuropharmacological agents / drugs, and the identification / validation of drug targets affecting the CNS in health and disease. We particularly encourage studies that provide insight into the mechanisms of drug action at the molecular level. Manuscripts containing evidence for genetic or epigenetic effects on neurochemistry or behavior are welcome.

Topics Covered (Recognized by AI)
Medicine98.5%Biology97.6%Psychology95.7%Internal medicine90.1%Neuroscience77.2%Chemistry73.9%Psychiatry72.2%Endocrinology71.2%Biochemistry69%Pharmacology68.4%Genetics62.3%Receptor56.5%Anesthesia44.4%Dopamine31.8%Pathology24.8%Antagonist22.4%
Primary Research Areas

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI
JCRSCIE2026

NEUROSCIENCES

Q2
Rank156/330
IndexSCIE
JCRSCIE2026

PHARMACOLOGY & PHARMACY

Q2
Rank149/356
IndexSCIE
JCRSCIE2026

PSYCHIATRY

Q2
Rank97/293
IndexSCIE
JCISCIE2026

NEUROSCIENCES

Q2
Rank121/330
IndexSCIE
JCISCIE2026

PHARMACOLOGY & PHARMACY

Q2
Rank95/356
IndexSCIE
JCISCIE2026

PSYCHIATRY

Q2
Rank102/293
IndexSCIE

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year
2026Latest
IF3.3
Articles / Year178
Total Citations38
2025
IF3.3
Articles / Year260
Total Citations626
2024
IF3.5
Articles / Year220
Total Citations1,409
2023
IF3.4
Articles / Year226
Total Citations2,441
2022
IF4.415
Articles / Year270
Total Citations4,707

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #3,914Scopus Q1SCImago Profile
Scopus Coverage:1959-2026
Scopus Broad Areas:Pharmacology, Toxicology and Pharmaceutics
Scopus Citation Rank (SJR)Q1
1.147

Weighted prestige citation metric per document indexed in the Scopus database.

Quartile: Scopus Q1
Citations / Doc (2 years)
3.38

Average citations received per document published in the 2-year window.

2-Year Citation Window
Estimated Publication Fee (APC)
$3,389 USD

Estimated Article Processing Charge for Open Access publication.

Estimated cost / article

Scopus 3-Year Publication & Citation Window

3-Year Citations2,548
3-Year Documents652
Citable Documents646

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)1

Citations in government and international policy documents

Female Author Rate47.7%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

PharmacologyQ1
Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth
Self-citation: 2.9%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):
3区 (Zone 3)Medicine
Minor Category (Specific Field):
3区NEUROSCIENCES
CAS Early Warning List History:
Updated annually: 2020 – 2024
2020
Not warned
2021
Not warned
2022
Not warned
2023
Not warned
2024
Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

Psychopharmacology (acronym: psph, abbr: PSYCHOPHARMACOLOGY, ISSN: 0033-3158) is a peer-reviewed international scholarly journal in the field of Medicine, published by Springer Berlin Heidelberg in Germany since 1959. The periodical holds a Journal Impact Factor (JIF) of 3.30, ranking in quartile Q2 of Web of Science (SCIE), a Scopus SJR indicator of 1.147 (Q1), an H-index of 224.

The journal enforces rigorous peer evaluation with a publication frequency of Semimonthly, an annual output of approximately 289 scientific articles. In terms of accessibility and author fees, it operates under the Hybrid model with an estimated APC of $3,389 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.

Publishing & Editorial Information

Detailed publisher, peer-review turnaround, and publication cycle specifications

Open Access Model
Hybrid
Publisher
Springer Berlin Heidelberg
Publication Language
English
Frequency
Semimonthly
Founding Year
1959
Indexing & Databases
SCIEScopusPubMed
Editorial Address
SPRINGER, 233 SPRING ST, NEW YORK, USA, NY, 10013

Similar Journals in Discipline

Journals in the same research field with comparable impact metrics

Record UUID: 365dd511-4008-4956-bacc-e00d42949fb2
Database Updated: 2026-10-01